
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Investor discussions on Scancell Holdings Plc (SCLP) recently reflected a mix of optimism and skepticism regarding the company's future prospects, particularly its advancements in cancer vaccine therapies. Participants highlighted the expansive market potential for melanoma treatments, with estimates suggesting the global adjuvant melanoma market could grow significantly from $7.4 billion (2022) to $18.62 billion by 2031. This backdrop prompted comments about Scancell's opportunity to capture a portion of this expansive market, with management's estimate suggesting a $9 billion true market size for melanoma therapeutics across all stages.
Despite this promise, there was evident frustration among some investors about the stock's performance over the years, particularly a comment that a potential return of 36p appeared "pretty piss poor" after a decade of development. This sentiment was echoed by other investors, some of whom expressed doubts about increasing their stakes at current prices, citing elevated risk levels. However, others remained optimistic, pointing towards promising trial results and the potential for partnerships with big pharmaceutical companies to provide non-dilutive funding. Notably, one user remarked, "the whole point as to why we are here is non-dilutive funding from Big Pharma," indicative of a cautious yet hopeful perspective. Overall, while investor sentiment reflected strong belief in the company's long-term potential, there remains a palpable concern regarding the timing of stock gains and the necessity for tangible results.
Show more
Scancell Holdings Plc reported significant developments in its interim results for the six months ending October 31, 2024. The company, based in Oxford, UK, experienced a pretax loss of GBP 13.8 million, attributed largely to a revaluation of derivative liabilities. Despite this financial setback, Scancell emphasized a strong cash position and notable advancements in its clinical development programs, particularly for its lead product, SCIB1, a DNA cancer vaccine. The ongoing SCOPE trial for advanced melanoma yielded encouraging interim results, revealing an 80% progression-free survival rate among 25 patients at six months, with 20% achieving a complete response.
The robust progress in clinical trials underscores Scancell's position in the biopharmaceutical sector, as it continues to innovate in the field of immunotherapy for cancer treatment. The company remains optimistic about its future, leveraging its recent financial improvements and research milestones to propel its product development forward. The results and updates from the recent interim report suggest that Scancell is strategically poised to capitalize on its advancements, even amid the challenges reflected in its financial performance.
Show more
Scinv_temp |
True. Nobody wants a moldy scientist. Seriously though, it is positive that this is no longer all about liar Lindy. It never really was anyway. |
its also good to see other Scientists within Scancell ... getting out and about |
Have you been at the magic mushrooms already? |
PFS:-The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. |
Moljen, I expect that we will not be at 9p when the data comes in for Modi-1 with doublet in RCC and iScib+. |
Aha, a poster. |
Last year they were invited to present at a prestigious IO session at AACR, and they presented results from a year before. This year, with substantially more data and confidence, just a poster. This is what happens when you are unprofessional. |
we are at Mk4 with 5 in the clinic and 6 progressing 7 and 8 are sitting in the wings and sister of Mk4 is ready couple that with MK9 tcr and Mk 10 cell therapy |
Hopefully we do something similar this year. |
I Overview |
I assume you know the market size for the Vaccine Ruck in this indication |
yes its called standard of care .... |
"which is why they consider $9 billion the true market size"* management estimate *This of course is the total global melanoma therapeutics markets, all stages and all treatment types. There will of course be a reasonable slice that Scancell can attempt to grab. |
Reform UK has won its first ever Welsh council seat in a landmark victory - with a higher vote share than Nigel Farage received in his constituency last year. |
which is why they consider $9 billion the true market size |
I know it is adjuvant Inan. Should make Scancell even more attractive. |
High flyers eh ....... |
basically scancell in effect has a training center for high flyers |
Room C209f Biodiscovery Institute |
Pipeline .......... |
About us |
There are so many cancers and subtypes |
Type | Ordinary Share |
Share ISIN | GB00B63D3314 |
Sector | Pharmaceutical Preparations |
Bid Price | 8.80 |
Offer Price | 9.00 |
Open | 9.20 |
Shares Traded | 100,606 |
Last Trade | 09:11:14 |
Low - High | 8.90 - 9.20 |
Turnover | 0 |
Profit | -5.86M |
EPS - Basic | -0.0057 |
PE Ratio | -15.61 |
Market Cap | 95.38M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions